



Biotech Daily

Tuesday November 1, 2016

Daily news on ASX-listed biotechnology companies

- * **OCTOBER BDI-40 DOWN 0.5%, ASX200 DOWN 2%, BIG CAPS DOWN 7%
- GENETIC SIGNATURES, COMPUMEDICS UP 42%; PRANA DOWN 34%**
- * **TODAY: ASX, BIOTECH DOWN: NEUREN UP 7%, CELLMID DOWN 9%**
- * **FEDERAL \$417m FOR 989 ARC GRANTS**
- * **REVA HAILS FANTOM II STENT TRIAL SAFETY DATA**
- * **CELLMID RAISES \$3m FOR EVOLIS HAIR LOSS US LAUNCH**
- * **MMJ REQUESTS 'CHANGED TRANSACTION' TRADING HALT**
- * **PROBIOTEC DIRECTORS REMOVAL AGM**
- * **CORRECTION: PRESCIENT**
- * **MEDADVISOR TO RELEASE 2.8m ESCROW SHARES**
- * **MEMPHASYS DIRECTOR ANDREW GOODALL TAKES 39%**
- * **UNILIFE APPOINTS ROSEMARY CRANE, DUANE DESISTO DIRECTORS**

MARKET REPORT

The Australian stock market fell 0.51 percent on Tuesday November 1, 2016 with the ASX200 down 27.2 points to 5,290.5 points. Eleven of the Biotech Daily Top 40 stocks were up, 21 fell, five traded unchanged and three were untraded.

Neuren was the best, up 0.3 cents or seven percent to 4.6 cents with 966,538 shares traded. Actinogen and Pro Medicus climbed more than five percent; Oncosil was up 4.8 percent; Bionomics, Clinuvel and Starpharma rose more than two percent; Genetic Signatures, Osprey and Viralytics were up more than one percent; with Opthea up 0.7 percent.

Cellmid led the falls, down 0.3 cents or 9.1 percent to three cents with 8.1 million shares traded. Prima lost 5.6 percent; Compumedics and IDT fell more than four percent; Airxpanders, Avita, Mesoblast, Pharmaxis and Psivida were down more than three percent; Admedus, Nanosonics, Orthocell and Prana shed more than two percent; Anteo, Cochlear, Cyclopharm, Factor Therapeutics, Impedimed, Medical Developments, Polynovo and Sirtex were down one percent or more; with CSL, Resmed and Reva down by less than one percent.

BIOTECH DAILY TOP 40 INDEX (BDI-40)

The Biotech Daily Top 40 Index (BDI-40) slipped half a percent in October, with a \$242 million fall by Sirtex dragging the index down, despite a mix of strong and modest rises.

The BDI-40 out-performed the ASX200 which fell 2.2 percent, the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) were down 7.2 percent and the Nasdaq Biotechnology Index fell 11.4 percent.

Twenty-three of the BDI-40 companies were up in October, five by more than 30 percent; 14 fell, three by more than 20 percent; with three companies unchanged.

For the year to October 31, 2016, the BDI-40 climbed 15.1 percent, the ASX200 was up 1.5 percent, with the Big Caps up a collective 8.0 percent.

Genetic Signatures was October's best, up 42.105 percent to \$54 million, beating Compumedics on Melbourne Cup Day by less than half a nose, up 42.056 percent to \$152 million. Clinuvel jumped 39.0 percent, followed by Benitec (35.7%), Avita (34.4%), Viralytics (22.8%), Factor Therapeutics (20.0%), Universal Biosensors (13.7%), Admedus (12.3%), IDT and Polynovo (11.5%), Mesoblast (10.4%) and Osprey (10.2%).


Prana led the falls, down 33.9 percent to \$37 million, followed by Psivida (29.3%), Dimerix (28.6%), Bionomics (17.2%), Sirtex (13.1%), Neuren, Oncosil and Pro Medicus (12.5%).

Outside the BDI-40, LBT jumped 172.7 percent to \$60 million on its US FDA plate assessment approval, Innate Immunotherapeutics climbed 44.1 percent to \$160 million (up 451.7 percent for the year to October 31) on hopes for its multiple sclerosis trial results due in September 2017, with Phosphagenics recovering and Volpara improving.

The Nasdaq Biotech Index fell 11.4 percent in October, with Aviragen (Biota) losing a further 34.0 percent to \$64 million, Sunshine Heart tumbling 60 percent to \$6 million and Israel's Redhill, developing Giaconda's assets, down 13.9 percent to \$199 million.

The three Big Caps fell a collective 7.2 percent. Cochlear fell 9.5 percent to \$7,347 million, Resmed lost 7.0 percent to \$11,028 and CSL shed 6.8 percent to \$45,825 million.

BDI-40 v ASX200 Jun 30, 2006 to Oct 31, 2016 - Adjusted



FEDERAL GOVERNMENT, AUSTRALIAN RESEARCH COUNCIL

The Federal Government says it has funded 989 Australian Research Council projects worth \$416.6 million to begin in 2017.

A media release from the Minister for Education and Training Simon Birmingham said the funding was part of the ARC National Competitive Grants Program.

The media release said that 630 Discovery Projects would receive \$234.7 million, 11 Indigenous grants would receive \$4.6 million; 200 Early Career Researcher Award projects would receive \$71.7 million, 100 Future Fellowships would receive \$77.0 million and 48 Linkage, Infrastructure, Equipment and Facilities grants would receive \$28.6 million.

Mr Birmingham said the funding was “a crucial investment in growing a smart Australia, driving innovation and delivering real outcomes that benefit all Australians”.

Details are at: www.arc.gov.au/november-2016-arc-major-grants-announcement.

REVA MEDICAL

Reva says that final safety data from its 240-patient Fantom bio-resorbable stent trial shows a 2.1 percent major adverse cardiac events rate and low late lumen loss.

Reva said that the Fantom II trial was evaluating the safety and the performance of the Fantom sirolimus-eluting bio-resorbable scaffold and enrolled a total of 240 patients in two cohorts.

The company said that it previously reported a major adverse cardiac event rate of 2.56 percent for the 117 patients enrolled in cohort A.

In May, Reva said the first cohort six-month results showed a 1.71 percent rate for major adverse cardiac events and angiographic imaging of the first 100 patients at six months showed that the treated coronary arteries had a mean in-segment late lumen loss or late loss of 0.21mm (BD: May 18, 2016).

The company said at that time that low late loss, the difference between the stented vessel diameter and follow-up at six months, was “a desirable result that historically corresponds to positive long-term outcomes and compares to permanent drug-eluting stents and competitive bio-resorbable scaffolds that generally have late loss values in the range of 0.20mm to 0.40mm”.

Today, Reva said that the 123 patients in cohort B had completed their six-month clinical assessment and the combined major adverse cardiac event rate for the entire patient population at six months was 2.1 percent.

The company said that the final in-scaffold late lumen loss for patients in cohort A was 0.25mm (± 0.40 mm) and an in-segment late lumen loss of 0.17 mm (± 0.34 mm), which compared favorably to the rates of commercially available competitive bio-resorbable scaffolds and drug-eluting stents.

Reva said that the data was presented by the Sao Paulo, Brazil-based Institute Dante Pazzanese of Cardiology’s invasive cardiology director and trial co-principal investigator Dr Alexandre Abizaid at the Transcatheter Cardiovascular Therapeutics conference in Washington DC, October 29 to November 2, 2016.

“The low [major adverse cardiac event] rate reported for the 240 patients treated with Fantom demonstrates a strong safety profile through this time point,” Dr Abizaid said.

Reva said that Skejby, Denmark-based Aarhus University Hospital’s research fellow Jo Simonsen presented six-month optical coherence tomography results on a sub-set of 73 patients in cohort A showing “continued vessel patency and promising healing results with 98 percent strut coverage at six months”.

Reva fell one cent or 0.8 percent to \$1.28.

CELLMID

Cellmid says its placement at three cents a share has received commitments for \$3 million from new and existing institutional and sophisticated investors.

Cellmid said the funds would be used for the US launch of the Evolis FGF5 inhibitor hair growth products.

The company said that in July its Advangen wholly-owned subsidiary signed a distribution partnership with the Dallas, Texas-based Colour Collective which specialized in hair product launches in the US.

Cellmid said that with the \$1.2 million raised through the exercise of options in October, the placement will allow it to invest in the Evolis launch, including product manufacture, digital and social media, salons and high end retail distribution.

Cellmid fell 0.3 cents or 9.1 percent to three cents with 8.1 million shares traded.

MMJ PHYTOTECH

MMJ has requested a trading halt "pending an announcement regarding a material change to the company's proposed transaction with Top Strike Resources".

In September, MMJ said it would spin-out subsidiaries United Greeneries and Satipharm through a back-door listing into Top Strike Resources for \$C40 million (\$A39.4 million).

MMJ said at that time that Top Strike was listed on the Calgary, Alberta-based Toronto Stock Exchange Venture Exchange and would pay \$C2.5 million in cash and the balance in scrip (BD: Sep 28, 2016).

Trading will resume on November 3, 2016 or on an earlier announcement.

MMJ last traded at 22.5 cents.

PROBIOTEC

Probiotec shareholders will vote to remove director chairman Robert Maxwell Johnston and Richard David Kuo.

In September, Probiotec founder and former executive director Charles Wayne Stringer was a signatory to a call to remove directors Robert Maxwell Johnston and Richard David Kuo (BD: Sep 23, 2016).

The September "notice of resolutions to be moved at a general meeting" said that Mr Stringer and Jane Elizabeth Stringer were directors of Inston Pty Ltd which held 13.105 percent of Probiotec and along with Rudolf Andrew Ganter and Laurel Mary Ganter who were directors of Ganter Corporation Pty Ltd which held 3.765 percent of the company, jointly called for the removal of the two directors.

There was no explanation for the call for the removal of the two directors.

According to ASX data, Mr Kuo was appointed a director on July 28, 2006 and Mr Johnston was appointed on April 27, 2010.

The removal resolutions follow resolutions to adopt the remuneration report and the election or re-election of directors Mr Kuo, Graham Morton, Geoffrey Ronald Pearce and Richard Charles Nicholson.

The meeting will be held at Probiotec, 83 Cherry Lane, Laverton North, Victoria, on November 29, 2016 at 10am (AEDT).

Probiotec fell half a cent or one percent to 49.5 cents.

PRESCIENT THERAPEUTICS

Last night's edition accidentally reported Prescient chief executive officer Steven Yatomi-Clarke's base salary as \$31,000, which was one order of magnitude short.

The company's notice of meeting said that Mr Yatomi-Clarke was paid a cash salary of \$310,000 a year plus \$19,308 in superannuation and was entitled to a performance-based bonus of up one-third of his cash salary.

The mistake was made by the former annual general meeting notice reporter.

Prescient was up half a cent or 4.8 percent to 11 cents.

MEDADVISOR

Medadvisor says that 2,779,962 shares will be released from escrow on November 12, 2016.

According to the company's most recent Appendix 3B new issue announcement, following the release, there would be 648,081,352 shares available for trading.

Medadvisor said that a further 354,694,811 shares remained in escrow.

Medadvisor was untraded at 3.9 cents.

MEMPHASYS (FORMERLY NUSEP)

Memphasys director Andrew Goodall says he has increased his shareholding from 220,167,289 (38.67%) to 223,171,598 shares (39.20%).

Mr Goodall said that he held a direct interest in Memphasys, as well as an indirect interest through Ti Rakau Developments and Aemagood Pty Ltd, with Mr Goodall acquiring 3,004,309 shares on market for \$17,907 or 0.6 cents a share.

Memphasys was up 0.2 cents or 40.0 percent to 0.7 cents with 100,000 shares traded.

UNILIFE CORP

Unilife says it has appointed Rosemary A Crane and Duane M DeSisto as directors.

Unilife chair Mary Kate Wold said that Ms Crane and Mr DeSisto had proven track records of leading successful life sciences organizations.

The company said that Ms Crane was previously Epocrates Inc chief executive officer and prior to Epocrates held senior executive positions at Johnson & Johnson, including over-the-counter and nutritional group chair and head of pharmaceutical marketing.

Unilife said that Ms Crane held senior executive roles at Bristol-Myers Squibb and was currently a director of Teva Pharmaceuticals and was Zealand Pharma AS vice-chair.

The company said that Ms Crane held a Bachelor of Arts from the State University of New York and a Master of Business Administration from Kent State University.

Unilife said that Mr DeSisto was Insulet Corp chief executive officer from 2003 to 2014 and previously was PaperExchange.com chief executive officer and chief financial officer, FGX International chief financial officer and Zoll Medical Corp chief financial officer.

The company said that Mr DeSisto held a Bachelor of Science from Rhode Island's Providence College and a Master of Business Administration from Rhode Island's Bryant College.

Unilife fell 0.4 cents or 6.15 percent to 6.1 cents.

BIOTECH DAILY TOP 40 WITH MARKET CAPITALIZATION AT OCT 31, 2016

Company \$Am	Nov-15	Oct-16	Nov-16
Cochlear	5,041	8,114	7,347
CSL	43,221	49,188	45,825
Resmed	11,177	11,858	11,028
BDI-20			
Admedus	123	81	91
Airxpanders	177	323	284
Bionomics	233	221	183
Clinuvel	125	290	403
Compumedics	56	107	152
Ellex	57	138	143
Impedimed	293	601	610
Medical Developments	190	317	311
Mesoblast	1,150	424	468
Nanosonics	454	1,006	1,033
Neuren	151	88	77
Opthea	37	110	113
Pharmaxis	75	86	86
Polynovo	59	156	174
Prima	115	79	75
Pro Medicus	329	583	510
Psivida	156	140	99
Reva	320	542	551
Sirtex	2,143	1,852	1,610
Viralytics	104	219	269
Second 20			
Acrux	125	57	57
Actinogen	36	25	23
Anteo	79	57	61
Atcor	59	20	19
Avita	56	64	86
Benitec	65	14	19
Cellmid	29	29	31
Cyclopharm	30	72	70
Dimerix	9	21	15
Factor Therapeutics	14	40	48
Genetic Signatures	38	38	54
IDT	75	52	58
Living Cell	22	38	40
Oncosil	59	56	49
Orthocell	34	28	29
Osprey	43	98	108
Prana	59	56	37
Starpharma	216	240	269
Universal Biosensors	73	51	58
Uscom	17	27	27

* Biotech Daily editor, David Langsam, owns shares in Acrux, Admedus, Benitec, Mesoblast, Nanosonics, Neuren, Volpara and non-biotechnology stocks. Through Australian Ethical Superannuation he has an indirect interest in a range of other biotechnology companies: <http://www.australianethical.com.au/who-we-invest-in>. These holdings are liable to change.

Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053
email: editor@biotechdaily.com.au; www.biotechdaily.com.au; twitter: @biotech_daily